Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
Rigel Pharmaceuticals (NASDAQ: RIGL) has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich brings over 25 years of experience in developing cellular immunotherapies for cancer treatment, with expertise in clinical drug development and translational research.
Currently serving as CEO of Indapta Therapeutics, Dr. Frohlich previously led portfolio strategy at Juno Therapeutics and served as CMO at Dendreon , where he led the development and regulatory approval of PROVENGE®. His background includes positions at UCSF as an assistant adjunct professor of hematology/oncology, with degrees from Yale College and Harvard Medical School.
Dr. Frohlich will contribute to advancing Rigel's hematology and oncology pipeline, particularly focusing on the IRAK1/4 and IDH1 inhibitor programs for lower-risk myelodysplastic syndrome and glioma treatments respectively.
Rigel Pharmaceuticals (NASDAQ: RIGL) ha nominato Mark W. Frohlich, M.D. nel suo Consiglio di Amministrazione. Il Dr. Frohlich porta con sé oltre 25 anni di esperienza nello sviluppo di immunoterapie cellulari per il trattamento del cancro, con competenze nello sviluppo di farmaci clinici e nella ricerca traslazionale.
Attualmente CEO di Indapta Therapeutics, il Dr. Frohlich ha precedentemente guidato la strategia del portafoglio presso Juno Therapeutics e ha ricoperto il ruolo di CMO presso Dendreon, dove ha guidato lo sviluppo e l'approvazione regolatoria di PROVENGE®. Il suo background include posizioni presso UCSF come professore associato di ematologia/oncologia, con lauree conseguito presso Yale College e la Harvard Medical School.
Il Dr. Frohlich contribuirà all'avanzamento della pipeline ematologica e oncologica di Rigel, concentrandosi in particolare sui programmi inibitori di IRAK1/4 e IDH1 per il trattamento della sindrome mielodisplastica a basso rischio e dei gliomi rispettivamente.
Rigel Pharmaceuticals (NASDAQ: RIGL) ha nombrado a Mark W. Frohlich, M.D. en su Junta Directiva. El Dr. Frohlich aporta más de 25 años de experiencia en el desarrollo de inmunoterapias celulares para el tratamiento del cáncer, con experiencia en el desarrollo de medicamentos clínicos y en la investigación traslacional.
Actualmente, es CEO de Indapta Therapeutics; el Dr. Frohlich anteriormente lideró la estrategia de cartera en Juno Therapeutics y fue CMO en Dendreon, donde dirigió el desarrollo y la aprobación regulatoria de PROVENGE®. Su experiencia incluye posiciones en UCSF como profesor adjunto de hematología/oncología, con títulos de Yale College y Harvard Medical School.
El Dr. Frohlich contribuirá al avance de la cartera de hematología y oncología de Rigel, enfocándose particularmente en los programas de inhibidores de IRAK1/4 e IDH1 para el tratamiento del síndrome mielodisplástico de bajo riesgo y gliomas, respectivamente.
리겔 제약 (NASDAQ: RIGL)은 마크 W. 프로흘리히, M.D.를 이사회에 임명했습니다. 프로흘리히 박사는 암 치료를 위한 세포 면역 요법 개발에 25년 이상의 경험을 가지고 있으며, 임상 약물 개발 및 전이 연구에 대한 전문성을 갖추고 있습니다.
현재 인답타 테라퓨틱스의 CEO로 재직 중인 프로흘리히 박사는 이전에 주노 테라퓨틱스에서 포트폴리오 전략을 이끌었고, 덴드레온에서 CMO로 활동하며 PROVENGE®의 개발 및 규제 승인을 이끌었습니다. 그의 경력에는 UCSF에서 혈액학/종양학의 부교수로 재직한 경험이 있으며, 예일 대학과 하버드 의대에서 학위를 받았습니다.
프로흘리히 박사는 리겔의 혈액학 및 종양학 파이프라인을 발전시키는 데 기여할 것이며, 특히 저위험 골수형성이상증후군 및 신경교종 치료를 위한 IRAK1/4 및 IDH1 억제제 프로그램에 집중할 것입니다.
Rigel Pharmaceuticals (NASDAQ: RIGL) a nommé Mark W. Frohlich, M.D. au sein de son Conseil d'Administration. Le Dr Frohlich apporte plus de 25 ans d'expérience dans le développement d'immunothérapies cellulaires pour le traitement du cancer, avec une expertise en développement de médicaments cliniques et en recherche translationnelle.
Actuellement PDG d'Indapta Therapeutics, le Dr Frohlich a précédemment dirigé la stratégie de portefeuille chez Juno Therapeutics et a été CMO chez Dendreon, où il a dirigé le développement et l'approbation réglementaire de PROVENGE®. Son parcours comprend des postes à l'UCSF en tant que professeur adjoint en hématologie/oncologie, avec des diplômes de Yale College et de la Harvard Medical School.
Le Dr Frohlich contribuera à l'avancement de la pipeline hématologique et oncologique de Rigel, en se concentrant particulièrement sur les programmes d'inhibiteurs IRAK1/4 et IDH1 pour le traitement du syndrome myélodysplasique à faible risque et des gliomes respectivement.
Rigel Pharmaceuticals (NASDAQ: RIGL) hat Mark W. Frohlich, M.D. in seinen Vorstand berufen. Dr. Frohlich bringt über 25 Jahre Erfahrung in der Entwicklung von zellulären Immuntherapien zur Krebsbehandlung mit, mit Fachkenntnissen in der klinischen Arzneimittelentwicklung und der translationale Forschung.
Derzeit als CEO von Indapta Therapeutics tätig, leitete Dr. Frohlich zuvor die Portfoliostrategie bei Juno Therapeutics und war CMO bei Dendreon, wo er die Entwicklung und die regulatorische Genehmigung von PROVENGE® leitete. Sein Hintergrund umfasst Positionen an der UCSF als außerordentlicher Professor für Hämatologie/Onkologie, mit Abschlüssen vom Yale College und der Harvard Medical School.
Dr. Frohlich wird zur Weiterentwicklung von Rigels Hämatologie- und Onkologie-Pipeline beitragen, insbesondere mit Fokus auf die IRAK1/4- und IDH1-Inhibitoren-Programme zur Behandlung des niedrig-risiko myelodysplastischen Syndroms und von Gliomen.
- Addition of board member with extensive experience in cancer immunotherapy development
- Strategic expertise in clinical development and regulatory approvals
- New director's successful track record with FDA-approved therapies (PROVENGE® and Breyanzi®)
- None.
"We are pleased to have Mark join our Board," said Raul Rodriguez, Rigel's president and CEO. "His experience in clinical development, translational research and portfolio strategy will be a valuable addition to Rigel as we advance our hematology and oncology development pipeline and grow our portfolio."
Dr. Frohlich currently serves as chief executive officer of Indapta Therapeutics, a privately-held biotechnology company focused on developing and bringing to market allogenic natural killer cell therapies to treat the still unmet medical needs of patients with cancer as well as autoimmune diseases. Prior to joining Indapta, Dr. Frohlich served as a consultant and strategic advisor for several immuno-oncology biotechnology companies. Before that, he led portfolio strategy at Juno Therapeutics, which developed the FDA-approved CAR T-cell therapy Breyanzi® for large B-cell lymphoma, until the company was sold to Celgene, now part of Bristol Myers Squibb. Prior to joining Juno, he held various roles at Dendreon Corporation, a pioneer in the development of cellular immunotherapy, with his most recent role being chief medical officer and executive vice president of Research & Development. At Dendreon, he led the clinical team responsible for the development and
Prior to joining Dendreon, Dr. Frolich was an assistant adjunct professor of hematology/oncology at the University of
"I am excited to join Rigel as it continues to advance its development pipeline," said Dr. Frohlich. "I believe the IRAK1/4 and IDH1 inhibitor programs have a significant potential to benefit patients with lower-risk myelodysplastic syndrome and glioma, respectively. I look forward to collaborating with the team as we further study these product candidates with the goal of bringing them to patients that need new treatment options."
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-appoints-mark-w-frohlich-md-to-board-of-directors-302396483.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
What expertise does Dr. Mark Frohlich bring to Rigel Pharmaceuticals (RIGL) board?
Which key therapeutic programs is RIGL currently developing?
What significant achievements has Dr. Frohlich accomplished in his career before joining RIGL?
How will Dr. Frohlich's appointment impact RIGL's development pipeline?
